A phase 1 dose escalation/expansion study of GSK5764227 (GSK'227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.

Bibliographic Details
Title:	A phase 1 dose escalation/expansion study of GSK5764227 (GSK'227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.
Authors:	Saif, Wasif M., Cassier, Philippe Alexandre, Curigliano, Giuseppe, Daniele, Gennaro, Hilton, John Frederick, Koganemaru, Shigehiro, Kowalyszyn, Ruben, LoRusso, Patricia, Moreno, Victor, Olmedo Garcia, Maria Eugenia, Perroud, Herman Andres, Symeonides, Stefan N., Yamamoto, Noboru, Aziez, Amine, Anjum, Rana, LaMacchia, John, Sembhi, Harjeet, Ratia, Nirav, Italiano, Antoine
Source:	Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, pTPS847-TPS847, 47p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2025.43.4_suppl.TPS847
Published in:	Journal of Clinical Oncology
Language:	English